Chris Chen, WuXi Biologics CEO (Photographer: Anthony Kwan/Bloomberg via Getty Images)
August 20, 2024 03:02 PM EDTUpdated 03:38 PM
China
Manufacturing

WuXi Bi­o­log­ics’ ADC spin­out re­ports rev­enue jump de­spite Biose­cure risk

Anna Brown

News Reporter

AD­Cs are so hot that WuXi Bi­o­log­ics’ spe­cial­ist com­pa­ny has so far ap­peared im­mune to the Biose­cure threat as it un­veiled a rise in rev­enues …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

J&J ex­pands Trem­fya in­to IBD with new FDA ap­proval

Ful­crum's Phase 3 for old GSK drug fails, stock sinks

A service from the Financial Times